When medications no longer provide patients with Parkinson's disease a reasonable quality of life due to the presence of levodopa-associated motor fluctuations and dyskinesias, surgical treatment is often pursued. Numerous studies have examined the antiparkinsonian efficacy of procedures currently a
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
โ Scribed by Katherine L. Widnell; Cynthia Comella
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- English
- Weight
- 132 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
โฆ Synopsis
Although levodopa remains the most effective drug for the symptomatic treatment of Parkinson's disease (PD), there are significant limitations to its chronic use. Growing preclinical and clinical evidence suggests that the severity of motor fluctuations is influenced both by PD severity and pulsatile stimulation of striatal dopamine receptors. Current management of motor fluctuations is based primarily on strategies to prolong the effects of dopaminergic stimulation. This prolongation is accomplished either through the use of long-acting dopaminergic drugs or prolonging of the effects of levodopa. During the past decade, the armamentarium of dopamine agonists increased and agents that prolong the plasma half-life of levodopa became available. Furthermore, recent clinical trials provide evidence-based approaches to improve the management of motor fluctuations in patients with advanced and early PD.
๐ SIMILAR VOLUMES
## Abstract Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, doubleโblind, doubleโdummy, controlled parallel group study, whic
A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn
## Abstract The motor effects of the partial dopamine agonist (โ)โ3โ(3โhydroxyphenyl)โNโnโpropylpiperidine [(โ)โ3โPPP, preclamol] were evaluated in nine patients with Parkinson's disease using a doubleโblind, placebocontrolled design. (โ)โ3โPPP monotherapy had an antiparkinsonian effect in five of